Skip to content

European, Multi-center, Exploratory Trial to Assess WEB Versus Other Endovascular Treatment in Ruptured Aneurysms.

WEB™ Embolization System in the Treatment of Acutely Ruptured Intracranial Aneurysms Versus Other Endovascular Techniques

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06511245
Acronym
WAVE
Enrollment
80
Registered
2024-07-19
Start date
2024-10-02
Completion date
2027-06-30
Last updated
2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ruptured Aneurysm

Brief summary

Comparison of efficacy and safety between WEB and other endovascular techniques

Interventions

Technique assigned through randomization

Sponsors

Microvention-Terumo, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Main Inclusion Criteria: * Patient is above 18 years of age at the time of consent * Patient has an identified acutely ruptured intracranial aneurysm requiring endovascular treatment (for the purposes of this study an acutely ruptured IA patient is defined as a patient with computed tomography (CT), magnetic resonance imaging (MRI), or lumbar puncture (LP) evidence of subarachnoid hemorrhage attributed to the index aneurysm within the last 30 days) * Aneurysm dome diameter must be ≤ 10mm and within the diameter (and parent vessel diameter, as appropriate) range treatable by commercially available WEB devices as well as at least one other alternative commercially available endovascular treatment device used per hospital standard practice * Aneurysm is located on the anterior communicating artery complex segment (ACom), internal carotid artery terminus (ICAt), anterior cerebral artery (ACA), middle cerebral artery (MCA), basilar apex, posterior communicating artery (PCom) or pericallosal artery * Patient must be neurologically stable with a Hunt & Hess score of I to III * Patient or patient's legally authorized representative (LAR) has provided written informed consent Main

Exclusion criteria

* Aneurysm to be treated is unsuitable for endovascular treatment with commercially available WEB devices and/or all other available endovascular treatment techniques used per standard site practice * Patient presenting as target aneurysm a blister like or dissecting aneurysm * Patient has more than one aneurysm requiring treatment within 30 days of completion of treatment of the target aneurysm * Patient with multiple aneurysms in whom ruptured aneurysm cannot be identified * Patient has pre-morbid mRS \> 2

Design outcomes

Primary

MeasureTime frameDescription
As exploratory design, one of the outcome will be the assessment of aneurysm occlusion at 12 months using Raymond-Roy scale.12 months (-3/+6 months)Raymond-Roy Classification is an angiographic classification including 3 classes, from class 1 (complete obliteration) to class 3 (aneurysm remnant).

Countries

France

Contacts

Primary ContactClinical Department
MVEClinicalEMEA@microvention.com+33(0)139217746

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026